BeiHai Bio Secures Nearly RMB 100 Million in New Financing to Accelerate Clinical Development of Multiple Innovative Oncology Drug Candidates

VCBeat (WeChat ID: vcbeat) has recently learned that Zhuhai Beihai Biotechnology Co., Ltd. (“Beihai Biotech”) announced the completion of a new round of financing amounting to nearly RMB 100 million.Guozhong Capital, Beijing Yishang Huicheng, Jiaxing Jinhu, Zhuhai Sci-Tech Innovation Investment, and other institutions jointly participated in this round of investment.. The funds raised in this round will be used to advance the clinical studies of the company’s innovative oncology drug projects, support the R&D of subsequent pipeline candidates, and continue to expand the team size, thereby accelerating the industrialization of the company’s product pipeline.

Beihai Biotech is a clinical-stage biopharmaceutical company dedicated to developing innovative oncology drugs that address unmet clinical needs. The company possesses a globally first-in-class new drug platform technology and sustained innovation capabilities, having developed more than 10 strategically synergistic innovative drug pipelines. Through independent research and development, it has filed over 70 invention patent applications and has been granted 13 invention patents in China and the United States.

Currently, Beihai Biotech has obtained Investigational New Drug (IND) approvals for multiple new drug candidates in both China and the United States. Among these, the BH009 program has commenced its first-in-human clinical trial and has successfully completed dosing in multiple patients. The company’s BH002 program received IND approval from the U.S. FDA this March. Two other new drug candidates (BH011 and BH006) are currently in the IND application stage, with Phase I clinical studies for multiple programs scheduled to initiate in the second half of the year. The fact that four innovative drug programs have entered or approached the clinical trial phase within a single year demonstrates Beihai’s independent innovation capabilities and the strong execution power of its team.

Since its establishment, the company has received a series of honors, including “Zhuhai Unicorn Seed Enterprise,” “Zhuhai Innovative and Entrepreneurial Team Introduction Program,” “Zhuhai Key Enterprise for Core Industrial and Technological Breakthroughs,” “Greater Bay Area New Productivity Unicorn Enterprise,” “Outstanding Enterprise at the 7th China Innovation and Entrepreneurship Competition (National Finals),” and “Most Investment-Worthy Project” at the 5th Rongchuang Dream Factory organized by the China Pharmaceutical Industry Information Center.

Regarding the completion of this round of financing,Dr. Sun Qun, Founder of Beihai Biotech“Beihai Biotech stated: ‘We are deeply honored to have earned the trust and support of numerous outstanding investment institutions in this round of financing, and we extend our special gratitude to our existing shareholder, Guozhong Capital, for its steadfast companionship. Multiple pipeline projects at Beihai Biotech have achieved significant milestone progress. This financing round will greatly facilitate Beihai’s leapfrog development, accelerate the enhancement of corporate value, and enable us to expedite clinical studies of our key products. We will continue to strengthen our innovation-driven, full-value creation capabilities, adhering to our development strategy of “maintaining a global perspective and focusing on clinical value,” to provide innovative drugs with superior efficacy for cancer patients worldwide, thereby substantially improving their quality of life.’”

Xie Bin, Guozhong Capital“Welcome to the new shareholders joining Beihai. Since the previous funding round, Guozhong Capital has had the privilege of accompanying and witnessing the company’s continuous breakthroughs in project R&D. The Beihai team has demonstrated remarkable growth speed and development potential, strategically laying out a tiered pipeline. Solid preclinical research data have fully substantiated the strong druggability of the pipeline, and its internationalization capabilities have been validated. In this round, Guozhong Capital continues to increase its investment. We will remain firmly committed to supporting Beihai’s long-term development. We are confident that under the leadership of Dr. Sun Qun, the company will achieve more significant milestones and advance toward becoming a first-class biotech enterprise.”

Beijing Yishang Huicheng and Dr. Longstated: “Beihai Biotech demonstrates a global perspective in its pipeline layout, consistently maintaining high R&D efficiency with encouraging progress in project advancement. We highly recognize the professional expertise and innovative spirit demonstrated by the Beihai team. We are committed to working alongside Dr. Sun and the Beihai team to further explore and cultivate Beihai’s potential, looking forward to steady and continuous progress in the company’s R&D projects, so as to benefit more patients at an earlier date.”

Xia Xin, Zhuhai Sci-Tech Innovation Investmentstated, “It is a great honor to participate in Beihai Biotech’s current funding round. The team at Beihai Biotech is an experienced and innovative entrepreneurial group, and we are delighted to grow alongside such a team. Beihai boasts a team with strong execution capabilities and a robust, well-balanced product pipeline. Extensive preclinical studies and validations have demonstrated its high druggability and significant commercial potential. As a municipal investment platform, Zhuhai Science and Technology Innovation Investment will leverage dual synergies in policy and industry to accelerate the company’s development. We believe that, with the support of this funding round, the company will continue to break through various stages of drug development, leveraging its professional team and strong R&D capabilities, and bring its products under development to market at an early date.”

Shenzhen Guozhong Venture Capital Management Co., Ltd. (hereinafter referred to as “Guozhong VC”) is a private equity investment institution specializing in the entrusted management of venture capital. It currently serves as the manager of the first physical fund with a scale of RMB 6 billion under the National Small and Medium-sized Enterprise Development Fund, namely the SME Development Fund (Shenzhen Limited Partnership). Guozhong VC advocates an investment philosophy that prioritizes research and integrates investment with research. By leveraging in-depth industry chain analysis to guide investment decisions, the firm focuses on opportunities in strategic emerging industries, with particular emphasis on outstanding enterprises in three key sectors: technological innovation, biopharmaceuticals and healthcare, and TMT (Technology, Media, and Telecom). Currently, the company has established a relatively comprehensive layout across several industry chains, including new energy vehicles, semiconductors and electronic components, and intelligent driving.

Zhuhai Science and Technology Venture Capital Co., Ltd. was established with capital contributions from the Zhuhai Municipal State-owned Assets Supervision and Administration Commission and Huafa Group, with an initial registered capital of RMB 1 billion in government funds. Zhuhai VC will implement an operational model characterized by “government guidance, market-oriented operation, and enterprise-style management.” It will focus on venture capital investment, park-based startup incubation and management, construction and operation of science and technology innovation parks, and technology-related services. By aggregating high-quality resources for innovation and entrepreneurship, it aims to become a leading national integrated science and technology innovation investment platform within the modern financial sector, driving the optimization, upgrading, and overall development of Zhuhai’s “Three Highs and One Specialty” industrial system.